Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tulobuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tulobuterol SCHEMBL31356434 | 1.00 | BLM (1.00) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL30986127 | 0.98 | ADRB2 (1.00) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL22970444 | 0.98 | ADRB2 (1.00) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL29866527 | 0.98 | ADRB2 (1.00) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL122692 | 0.98 | ADRB2 (1.00) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL28319125 | 0.94 | ADRB2 (0.91) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL28679569 | 0.91 | ADRB2 (0.85) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL28687422 | 0.91 | ADRB2 (0.85) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| Tulobuterol SCHEMBL28667223 | 0.91 | ADRB2 (0.85) | BLMADRB2ADRB1HIF1ACYP2D6 | |
| SCHEMBL11747685 | 0.85 | ADRB1 (0.77) | BLMADRB2ADRB1HIF1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649960-A1 | USE OF LONG-ACTING ß2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | Hong Kong Sxmeterol Pharmaceutical Co., Limited (HK) | 2025-11-19 | — | — | EP | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| WO-2024160057-A1 | USE OF LONG-ACTING β2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | 上海市第十人民医院 | 2024-08-08 | — | — | WO | claimed |
| CN-116082133-A | Synthetic method of tulobuterol | 上海医药工业研究院 | 2023-05-09 | — | — | CN | claimed |
| WO-2023039548-A1 | KINASE INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | FRED HUTCHINSON CANCER CENTER (US) | 2023-03-16 | — | — | WO | claimed |
| CN-110590569-B | Method for synthesizing tulobuterol | 杭州百诚医药科技股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113791162-B | Method for determining 35 chemical components illegally added in patch for relieving cough and asthma of children | 潍坊市检验检测中心 | 2022-02-08 | — | — | CN | claimed |
| CN-108290990-B | Adhesive polymer and medical adhesive patch | 帝国制药株式会社 | 2022-02-01 | — | — | CN | claimed |
| CN-113791162-A | Method for determining 35 chemical components illegally added in patch for relieving cough and asthma of children | 潍坊市检验检测中心 | 2021-12-14 | — | — | CN | claimed |
| CN-113354800-A | PEG block poly (glycolide-lactide) and application thereof | 山东谷雨春生物科技有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020146445-A1 | Stretchable patch | TEIJIN LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1177786-A1 | STRETCHABLE PATCH | TEIJIN LIMITED (JP) | 2002-02-06 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0188040-B1 | SLOW RELEASE SOLID PREPARATION | ABBOTT LABORATORIES LIMITED (GB) | 1991-08-14 | — | — | EP | claimed |
| US-4842866-A | ACTIVE MATERIAL IN BLEND OF ALGINATES | ABBOTT LABORATORIES LTD. (GB) | 1989-06-27 | — | — | US | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| EP-0188040-A1 | Slow release solid preparation | ABBOTT LABORATORIES LIMITED (GB) | 1986-07-23 | — | — | EP | claimed |